The results of the use of the phytopreparation Tadimax in the treatment of 60 men with mild and moderate lower urinary tract symptoms (LUTS) developed as a result of benign enlargement of the prostate gland are presented. The average age of the patients was 66.5 3.8 years. Tadimax was prescribed 2 tablets 3 times a day, in courses of 7 days with 7 day breaks for 3 months (a total of 6 courses). The data obtained indicate high efficacy and good tolerability of treatment. A decrease in the severity of LUTS was noted in 59 (96.6%) patients, which was accompanied by significant changes in objective clinical indicators: a decrease in residual urine volume and an increase in urine flow rate. Tadimax is a combined preparation, which includes extracts of several medicinal plants, and the main component is Crinum latifolium. The therapeutic effect of Tadimax is based on anti-inflammatory, antiproliferative and immunotropic action.
15 December 2021 in Urology Reports (St. - Petersburg)
BACKGROUND: Increasing the effectiveness of treatment of patients with symptoms of the lower urinary tract is one of the main problems of modern urology, which is associated both with their high prevalence and with a significant deterioration in the quality of life of patients. AIM: The article presents the results of the usage of the entomological drug Adenoprosin in the combined treatment of patients with lower urinary tract symptoms due to benign prostatic enlargement. MATERIALS AND METHODS: 80 patients were treated (mean age 63.6 6.4 years). At the initial phase of the study, all patients received Tamsulosin 0.4 mg once a day for 4 weeks. At the second phase, the patients were divided into two groups. Group 1 patients were prescribed a combination therapy with Adenoprosin (1 rectal suppository (150 mg) at night, for a course of 30 suppositories) and Tamsulosin (0.4 mg per day). Patients of the 2nd group continued monotherapy with Tamsulosin (0.4 mg per day). The duration of the second phase of treatment was 4 weeks. RESULTS: The results of the study showed a more pronounced positive dynamics of clinical indicators in patients of the 1st group, who received combination therapy with Adenoprosin and Tamsulosin, compared to patients of the 2nd group. There was a more pronounced decrease in the IPSS score, an improvement in the quality of life, an increase in the urine flow rate and a decrease in the volume of residual urine. The volume of the prostate gland did not change significantly. When examined 2 weeks after the end of treatment, the positive dynamics of clinical indicators in patients of the 1st group persisted. The tolerability of the treatment was satisfactory in patients of both groups. CONCLUSIONS: The results of the study indicate the advisability of including Adenoprosin in the combination therapy of patients with lower urinary tract symptoms due to benign enlargement of the prostate gland.
31 July 2022 in Urology Reports (St. - Petersburg)
BACKGROUND: The frequency of occurrence reaches premature ejaculation (PE) in young men reaches 30%. Increasing the effectiveness of treatment of patients with PE is one of the important problems of urology. AIM: Evaluation of the effectiveness of treatment of young patients with premature ejaculation with the phosphodiesterase 5-type inhibitor Tadalafil-SZ in monotherapy and in combination with behavioral therapy, as well as its comparison with the appointment of only behavioral therapy and placebo. MATERIALS AND METHODS: We observed 70 men with premature ejaculation aged 18 to 25 years. All patients were divided into 4 groups. Patients of the 1st group (n = 20) were prescribed Tadalafil-SZ at a dose of 5 mg once a day as monotherapy, patients of the 2nd group (n = 20) received behavioral therapy according to the startstop method; patients of the 3rd group (n = 20) were prescribed a combination therapy with Tadalafil-SZ at a dose of 5 mg per day together with the startstop behavioral technique; patients of the 4th group (n = 10) were prescribed a placebo. The duration of treatment is 30 days. Control examinations were performed before the start of treatment, immediately after its completion and 2 months after the end of therapy. To assess ejaculatory function the PEDT and AIPE questionnaires were used, as well as the IELT test. RESULTS: After the end of the 30-day course of treatment in patients of the 1st and 3rd groups, a significant increase in the duration of sexual intercourse by 22.5 times was noted compared with the values before treatment, as well as with the values in patients of the 4th group who received placebo. In patients of the 2nd group, we did not notice significant changes in comparison with the indicators before treatment in terms of the total scores of the PEDT questionnaire and the results of the IELT test, however, an increase in the total scores of the AIPE questionnaire was found. In patients of the 4th control group, there was no improvement in any of the tests performed. 2 months after the end of treatment, patients of the 1st group noted a return to the initial duration of sexual intercourse. The effect of the treatment was noted only in patients of the 3rd group, in whom during the control examination after 2 months the duration of sexual intercourse was significantly higher compared to the initial values before the start of treatment. CONCLUSIONS: The results of the study indicate the high efficiency of the phosphodiesterase 5-type inhibitor Tadalafil-SZ in the treatment of patients with premature ejaculation. The best results of treatment were achieved with the combined use of drug and behavioral therapy.
22 January 2023 in Urology Reports (St. - Petersburg)
BACKGROUND: Alpha-blockers are the first-line treatment for the elimination of symptoms of impaired urination due to benign prostatic hyperplasia. At the same time, the focus is not only on efficiency, but also on the safety of their appointment. AIM: Comparison of the efficacy and tolerability of the alpha1-blocker tamsulosin at a dosage of 0.2 mg twice a day and 0.4 mg once a day in patients with benign prostatic hyperplasia presenting with mild to moderate LUTS. MATERIALS AND METHODS: The study is based on the results of examination and treatment of 90 patients with symptoms of impaired urination in benign prostatic hyperplasia, aged 50 to 80 years. In the 1st group (n = 45) patients received tamsulosin 0.2 mg twice a day, in the 2nd group (n = 45) 0.4 mg once a day. The duration of treatment was 4 weeks. RESULTS: In patients of both groups, according to the IPSS questionnaire, a statistically significant decrease in the severity of obstructive and irritative symptoms, an improvement in the quality of life, an increase in the maximum urine flow rate, and a decrease in the volume of residual urine were revealed. When comparing the dynamics of clinical indicators in patients of the 1st and 2nd groups, no significant differences were found between the groups. At the same time, treatment tolerance was somewhat better in patients of the 1st group, which manifested itself in a smaller number of adverse events from the cardiovascular system and ejaculatory function disorders. CONCLUSIONS: The results of the study demonstrate the same efficacy of tamsulosin 0.2 mg twice a day and 0.4 mg once a day. At the same time, taking tamsulosin at a dose of 0.2 mg twice a day was characterized by better tolerability of therapy.
The review article is devoted to the history of surgical treatment of the ureteropelvic junction obstruction. The data on the main stages of development and improvement of the operative technique are presented, the main methods of restoring the outflow of urine from the kidney with strictures of the ureteropelvic junction are described. The analysis of modern methods of surgical treatment of this category of patients has been carried out.
The OBJECTIVE of the study was to analyze the results and to introduce our experience of the laparoscopic pyeloplasty regarding the stricture of the pyeloureteral segment.METHODS and MATERIALS. Our study represents results of treatment of 114 patients who had surgical treatment during the years 2013–2018. In that period, we made 114 primaries and 9 secondaries laparoscopic pyeloplasties with transperitoneal access. In this account, there were 43 men aged from 19 to 64 years, average age was (34.9±3.7), and 71 women aged from 19 to 77 years, average age was (39.2±4.2). All patients underwent ultrasound examination of the kidneys on the day of discharge and 3-5 days after stent extraction. Control examination, which included history taking, examination, clinical and biochemical blood analyses, clinical urine analysis and ultrasound of the kidneys were performed after 3 months. Plain and excretory urography were performed 6 and 18 months after surgical intervention. RESULTS. Operative removal of the stricture of the pyeloureteral segment was successful in 105 (92.2 %) out of 114 cases. 9 patients (7.8 % of the total number of operated patients) underwent repeated laparoscopic pyeloplasty. Duration stay after primary laparoscopic pyeloplasty was from 3 to 5 days, on average (3.9±0.7) days. Postoperative period after secondary pyeloplasty was without complications, the bed-day was from 3 to 6 days, on average (4.3±0.6) days.CONCLUSION. Our opinion is that the optimal method for surgical treatment of patients with primary and secondary strictures of the pyeloureteral segment is laparoscopic pyeloplasty. This kind of surgery has a favorable security profile and optimal postoperative results. Considering the possible causes of relapse of the stricture of the pyeloureteral segment, we came to the conclusion that the frequency of relapse is mainly connected with selected suture material, which determines the severity of scar changes.